RS68181B1 - Kristalni (r)-5-karbamoilpiridin-3-il-2-metil-4-(3-(trifluormetoksi)benzil) piperazin-1-karboksilat, kompozicije i metode njihove upotrebe - Google Patents

Kristalni (r)-5-karbamoilpiridin-3-il-2-metil-4-(3-(trifluormetoksi)benzil) piperazin-1-karboksilat, kompozicije i metode njihove upotrebe

Info

Publication number
RS68181B1
RS68181B1 RS20260687A RSP20260687A RS68181B1 RS 68181 B1 RS68181 B1 RS 68181B1 RS 20260687 A RS20260687 A RS 20260687A RS P20260687 A RSP20260687 A RS P20260687A RS 68181 B1 RS68181 B1 RS 68181B1
Authority
RS
Serbia
Prior art keywords
dosage form
methyl
benzyl
crystalline
carbamoylpyridin
Prior art date
Application number
RS20260687A
Other languages
English (en)
Serbian (sr)
Inventor
Lianfeng Huang
Nancy Tsou
Nicole Suzanne White
Jun Xu
Qun Zhang
Original Assignee
Lundbeck La Jolla Research Center Inc
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck La Jolla Research Center Inc, Celgene Corp filed Critical Lundbeck La Jolla Research Center Inc
Publication of RS68181B1 publication Critical patent/RS68181B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
RS20260687A 2018-09-13 2019-09-12 Kristalni (r)-5-karbamoilpiridin-3-il-2-metil-4-(3-(trifluormetoksi)benzil) piperazin-1-karboksilat, kompozicije i metode njihove upotrebe RS68181B1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862731014P 2018-09-13 2018-09-13
EP24185102.1A EP4434583B1 (en) 2018-09-13 2019-09-12 Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
RS68181B1 true RS68181B1 (sr) 2026-06-30

Family

ID=68069873

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20260687A RS68181B1 (sr) 2018-09-13 2019-09-12 Kristalni (r)-5-karbamoilpiridin-3-il-2-metil-4-(3-(trifluormetoksi)benzil) piperazin-1-karboksilat, kompozicije i metode njihove upotrebe
RS20241039A RS65967B1 (sr) 2018-09-13 2019-09-12 Kristalni (r)-5-karbamoilpiridin-3-il-2-metil-4-(3-(trifluorometoksi)benzil) piperazin-1-karboksilat, kompozicije i metode njegove upotrebe

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20241039A RS65967B1 (sr) 2018-09-13 2019-09-12 Kristalni (r)-5-karbamoilpiridin-3-il-2-metil-4-(3-(trifluorometoksi)benzil) piperazin-1-karboksilat, kompozicije i metode njegove upotrebe

Country Status (28)

Country Link
US (4) US11053199B2 (cg-RX-API-DMAC7.html)
EP (3) EP3849970B1 (cg-RX-API-DMAC7.html)
JP (1) JP7405840B2 (cg-RX-API-DMAC7.html)
KR (1) KR102844245B1 (cg-RX-API-DMAC7.html)
CN (3) CN118561814A (cg-RX-API-DMAC7.html)
AU (1) AU2019337623B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021004340A2 (cg-RX-API-DMAC7.html)
CA (1) CA3112200A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000596A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021003295A2 (cg-RX-API-DMAC7.html)
DK (2) DK4434583T5 (cg-RX-API-DMAC7.html)
EA (1) EA202190511A1 (cg-RX-API-DMAC7.html)
ES (2) ES2993173T3 (cg-RX-API-DMAC7.html)
FI (2) FI3849970T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20260757T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068147T2 (cg-RX-API-DMAC7.html)
IL (1) IL281276B2 (cg-RX-API-DMAC7.html)
LT (2) LT3849970T (cg-RX-API-DMAC7.html)
MA (2) MA71839B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021002923A (cg-RX-API-DMAC7.html)
MY (2) MY208901A (cg-RX-API-DMAC7.html)
PL (2) PL3849970T3 (cg-RX-API-DMAC7.html)
PT (2) PT4434583T (cg-RX-API-DMAC7.html)
RS (2) RS68181B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202102143RA (cg-RX-API-DMAC7.html)
SI (1) SI3849970T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202600252T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020056105A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2993173T3 (en) 2018-09-13 2024-12-23 Celgene Corp Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007010076A (es) * 2005-02-17 2007-10-16 Astellas Pharma Inc Derivado de heterociclico-1-carboxilato que contiene nitrogeno no aromatico de piridilo.
EP3099332A4 (en) * 2014-01-29 2017-06-21 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
PT3595665T (pt) * 2017-03-13 2024-11-21 Lundbeck La Jolla Research Center Inc Inibidores duplos de magl e faah
ES2993173T3 (en) 2018-09-13 2024-12-23 Celgene Corp Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof

Also Published As

Publication number Publication date
KR20210057789A (ko) 2021-05-21
US11053199B2 (en) 2021-07-06
MA53607A (fr) 2021-12-22
EP4434583A2 (en) 2024-09-25
JP2022500441A (ja) 2022-01-04
HUE068147T2 (hu) 2024-12-28
KR102844245B1 (ko) 2025-08-11
ES2993173T3 (en) 2024-12-23
WO2020056105A9 (en) 2020-07-09
MX2021002923A (es) 2021-09-08
FI4434583T3 (fi) 2026-05-15
HRP20260757T1 (hr) 2026-08-14
EP4434583B1 (en) 2026-04-01
PL3849970T3 (pl) 2025-01-07
AU2019337623A1 (en) 2021-05-13
US20210363105A1 (en) 2021-11-25
LT3849970T (lt) 2024-10-10
US20260062384A1 (en) 2026-03-05
US11680046B2 (en) 2023-06-20
PL4434583T3 (pl) 2026-07-20
DK4434583T5 (da) 2026-07-06
EP4434583A3 (en) 2024-11-20
SG11202102143RA (en) 2021-04-29
MY208901A (en) 2025-06-09
EP3849970A1 (en) 2021-07-21
CA3112200A1 (en) 2020-03-19
AU2019337623B2 (en) 2024-12-05
IL281276A (en) 2021-04-29
SMT202400369T1 (it) 2024-11-15
EP4768081A2 (en) 2026-07-01
EA202190511A1 (ru) 2021-07-05
EP3849970B1 (en) 2024-07-03
SMT202600252T1 (it) 2026-07-16
PT3849970T (pt) 2024-09-25
SI3849970T1 (sl) 2024-11-29
IL281276B2 (en) 2025-01-01
IL281276B1 (en) 2024-09-01
CN113227069B (zh) 2024-11-05
MY210363A (en) 2025-09-13
CL2021000596A1 (es) 2021-07-30
LT4434583T (lt) 2026-06-25
DK4434583T3 (da) 2026-06-15
PT4434583T (pt) 2026-06-11
US12410133B2 (en) 2025-09-09
US20200095201A1 (en) 2020-03-26
WO2020056105A1 (en) 2020-03-19
MA53607B1 (fr) 2025-05-30
RS65967B1 (sr) 2024-10-31
HRP20241294T1 (hr) 2024-12-06
JP7405840B2 (ja) 2023-12-26
CN118530218A (zh) 2024-08-23
FI3849970T3 (fi) 2024-09-20
CO2021003295A2 (es) 2021-07-30
ES3072981T3 (en) 2026-07-07
US20230382861A1 (en) 2023-11-30
MA71839B1 (fr) 2026-05-26
CN113227069A (zh) 2021-08-06
BR112021004340A2 (pt) 2021-05-25
CN118561814A (zh) 2024-08-30
DK3849970T3 (da) 2024-09-30